NRSN vs. KYTX, GNLX, ATOS, TARA, CCCC, PROC, HURA, ANIX, HLVX, and CTNM
Should you be buying NeuroSense Therapeutics stock or one of its competitors? The main competitors of NeuroSense Therapeutics include Kyverna Therapeutics (KYTX), Genelux (GNLX), Atossa Genetics (ATOS), Protara Therapeutics (TARA), C4 Therapeutics (CCCC), Procaps Group (PROC), TuHURA Biosciences (HURA), Anixa Biosciences (ANIX), HilleVax (HLVX), and Contineum Therapeutics (CTNM). These companies are all part of the "pharmaceutical products" industry.
NeuroSense Therapeutics vs. Its Competitors
NeuroSense Therapeutics (NASDAQ:NRSN) and Kyverna Therapeutics (NASDAQ:KYTX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, media sentiment, profitability and risk.
NeuroSense Therapeutics has higher earnings, but lower revenue than Kyverna Therapeutics. NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks.
NeuroSense Therapeutics' return on equity of 0.00% beat Kyverna Therapeutics' return on equity.
NeuroSense Therapeutics has a beta of 1.66, suggesting that its stock price is 66% more volatile than the S&P 500. Comparatively, Kyverna Therapeutics has a beta of 2.95, suggesting that its stock price is 195% more volatile than the S&P 500.
In the previous week, NeuroSense Therapeutics had 1 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 4 mentions for NeuroSense Therapeutics and 3 mentions for Kyverna Therapeutics. Kyverna Therapeutics' average media sentiment score of 1.65 beat NeuroSense Therapeutics' score of 0.47 indicating that Kyverna Therapeutics is being referred to more favorably in the news media.
1.0% of NeuroSense Therapeutics shares are held by institutional investors. Comparatively, 18.1% of Kyverna Therapeutics shares are held by institutional investors. 27.4% of NeuroSense Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
NeuroSense Therapeutics currently has a consensus price target of $14.00, indicating a potential upside of 601.40%. Kyverna Therapeutics has a consensus price target of $18.50, indicating a potential upside of 378.65%. Given NeuroSense Therapeutics' higher possible upside, equities research analysts plainly believe NeuroSense Therapeutics is more favorable than Kyverna Therapeutics.
Summary
Kyverna Therapeutics beats NeuroSense Therapeutics on 8 of the 14 factors compared between the two stocks.
Get NeuroSense Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NRSN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NRSN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NeuroSense Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:NRSN) was last updated on 7/16/2025 by MarketBeat.com Staff
Free NRSN Stock Alerts